Clinical trials: Breast Tumor Tissue
Breast Cancer, Breast Diseases
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
This study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms
- Trial name
- PECP (NCT03756090)
- Testing
- Palbociclib, Epirubicin, Cyclophosphamide
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions…
- Trial name
- PRART (NCT04175210)
- Testing
- Radiation therapy - 3 weeks, Radiation therapy - 2 weeks
- Where
- 3 sites in United States
- Volunteers
- 397 people
- Sponsor
- Weill Medical College of Cornell University
Breast Cancer, Breast Neoplasm
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
- Trial name
- NCT06075810
- Testing
- MBQ-167
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 48 people
- Sponsor
- MBQ Pharma
Triple Negative Breast Neoplasms
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
- Trial name
- CAPItello-290 (NCT03997123)
- Testing
- Capivasertib, Paclitaxel
- Where
- 260 sites in United States, Argentina and 28 more
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
Breast Cancer
Effect of Vitamin C and E in Breast Cancer Patients Undergoing Chemotherapy
Title: Effect of Vitamin C and Vitamin E in Breast Cancer patients undergoing Chemotherapy. Purpose of the study: The present study has been designed to assess the effects of vitamin C and vitamin E superimposed upon…
- Trial name
- NCT04463459
- Testing
- Vitamin C, Vitamin E
- Where
- Bangladesh
- Volunteers
- 80 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Breast Cancer
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
- Trial name
- NCT04514419
- Testing
- HS627, Pertuzumab
- Where
- China
- Volunteers
- 408 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Breast Cancer, Breast Carcinoma
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Background: Breast cancer is the most common cancer among women. It can often spread to the liver, lungs, bones, or brain. Breast cancer that spreads to the brain is often fatal.
- Conditions
- Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
- Trial name
- NCT07619534
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer
Only 59% of women with breast cancer (BC) treated with Endocrine Therapy (ET) remain compliant one year upon initial prescription, despite its proven effectiveness in reducing recurrence and improving survival.
- Trial name
- COMPLIANCE (NCT04176809)
- Testing
- Routine Assessment of HRQoL coupled with Therapeutic Information
- Where
- France
- Volunteers
- 342 people
- Sponsor
- Centre Georges Francois Leclerc
Breast Cancer, Breast Carcinoma
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.
- Conditions
- Breast Cancer, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT06145399
- Testing
- 18F-FDG PET/CT, [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging, 18F-FDHT
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastasis Breast
Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer
The study is designed to assess the treatment outcomes following treatment with letrozole plus metronomic capecitabine in patients with hormone receptor-positive, Her2-negative advanced breast cancer who have not received prior…
- Trial name
- NCT04942899
- Testing
- letrozole
- Volunteers
- 70 people
- Sponsor
- Assiut University
Metastatic Breast Cancer, Estrogen-receptor-positive Breast Cancer
The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity
The goal of this clinical trial is to test a physical activity program in patients with metastatic breast cancer and overweight receiving endocrine-based treatment.
- Conditions
- Metastatic Breast Cancer, Estrogen-receptor-positive Breast Cancer, Adiposity
- Trial name
- NCT06343987
- Testing
- Physical Activity
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Aarhus University Hospital
Malignant Neoplasm of Breast
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
Compare the effect of paravertebral block (PVB) with Ropivacaine or placebo on the incidence of chronic pain 3 months after breast cancer surgery.
- Trial name
- MIRs03 (NCT02408393)
- Testing
- Saline, Ropivacaine
- Where
- 6 sites in France
- Volunteers
- 380 people
- Sponsor
- Institut Curie
Breast Neoplasms
Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient
The purpose of this study is to evaluate the safeness and effectiveness of mix vaccine (MV). Enrolled patients will receive standard treatment according to National Comprehensive Cancer Network (NCCN) guide line with or without…
- Trial name
- NCT02338804
- Testing
- MV, standard treatment
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Breast Cancer
Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
The purpose of this study is to assess Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Complete 5 Years of Toremifene
- Trial name
- LEXTOP (NCT01072318)
- Testing
- Letrozole
- Where
- South Korea
- Volunteers
- 495 people
- Sponsor
- Korean Breast Cancer Study Group
Breast Cancer, Ovarian Cancer
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Background: Carboplatin is approved by the Food and Drug Administration to treat cancer. AZD2281 is an experimental drug in a class of agents called PARP inhibitors.
- Trial name
- NCT01445418
- Testing
- AZ2281 + Carboplatin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Breast, Alzheimer Disease
Decisions About Cancer Screening in Alzheimer's Disease
The Decisions about Cancer screening in Alzheimer's Disease (DECAD) study tests if an evidence-based decision aid for dementia caregivers can support decision-making about mammography and improve the quality of medical…
- Trial name
- DECAD (NCT03282097)
- Testing
- DECAD decision aid, Home safety guide
- Where
- 5 sites in United States
- Volunteers
- 442 people
- Sponsor
- Indiana University
Breast Cancer
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- SOLE (NCT00553410)
- Testing
- Letrozole
- Where
- 164 sites in United States, Australia and 18 more
- Volunteers
- 4,884 people
- Sponsor
- ETOP IBCSG Partners Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.